NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Teleflex Incorporated TFX
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.0B
▲ 17.2% vs FY2024
EPS · FY25
$-20.25
Dividend / sh · FY25
$1.36
Payout · FY25
-7%
ROE · FY25
-24.5%
Net margin · FY25
-45.4%
Dividend coverage
-14.9×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.0B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
The company lost 45 cents on every revenue dollar this year.
Per share
USD -20.25
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
-24.5%
Return on equity, FY2025
ROE
Operating margin5.9%
Net margin-45.4%
Return on assets-12.9%
Each USD of equity lost 24 cents this year.
Returned to shareholders
USD 360.3M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 60.3M
Net buybacksUSD 300.0M
Share of profit-39.8%
Consecutive raises—
USD 60.3M in dividends and USD 300.0M in buybacks went back to shareholders in a year without profit.
Growth
−4.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−10.6%
−4.7%
+1.0%
+2.4%
Dividend / share
+0.0%
+0.0%
+0.0%
+0.0%
Returned to shareholders
+78.1%
+41.6%
+20.3%
+13.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 6.9B
total assets, end of FY2025
Total assetsUSD 6.9B
EquityUSD 3.1B
CashUSD 378.6M
Gross debtUSD 2.6B
Net debtUSD 2.3B
Current ratio2.54×
Net debt stands at 72% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
2.0
1.7
1.7
2.8
2.8
2.5
2.6
2.4
2.1
1.9
1.8
1.8
1.7
1.6
1.5
1.4
1.4
1.9
Operating income $B
0.1
0.1
0.3
0.5
0.6
0.4
0.4
0.3
0.4
0.3
0.3
0.3
0.2
−0.1
0.2
0.2
0.3
0.2
EBITDA $B
0.2
0.2
0.3
0.6
0.7
0.5
0.5
0.4
0.4
0.4
0.4
0.3
0.3
−0.1
0.3
0.3
0.3
0.3
Income tax $B
−0.0
−0.0
0.0
0.1
0.1
0.0
−0.1
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.9
0.1
0.4
0.4
0.5
0.3
0.5
0.2
0.2
0.2
0.2
0.2
0.2
−0.2
0.3
0.2
0.3
0.1
EPS, diluted $
−20.25
1.48
7.53
7.68
10.23
7.09
9.80
4.29
3.27
4.98
5.10
4.04
3.45
−4.65
7.92
4.99
7.59
3.01
Dividend / sh $
1.36
1.36
1.36
1.36
1.36
1.36
1.36
1.36
1.36
1.36
1.36
1.36
1.36
1.36
1.36
1.36
1.36
1.34
Payout %
−7
91
18
18
13
19
14
31
40
25
23
30
37
−29
17
27
18
44
ROE %
−24.5
1.6
8.4
9.3
13.7
10.6
16.7
8.1
6.7
11.4
12.5
9.8
8.2
−10.1
17.2
12.0
19.2
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
70 of 70
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed